Core Viewpoint - Yuan Dong Bio (688513) announced that its wholly-owned subsidiary Chengdu Youluo Biotechnology Co., Ltd. has initiated Phase I clinical trials for its monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first patient dosing recently completed [1] Company Summary - EP-0210 is a humanized IgG1 monoclonal antibody that targets TNF-like ligand 1A (TL1A), aiming to treat inflammatory bowel disease by effectively binding to TL1A and blocking pro-inflammatory signaling pathways [1] - The development of TL1A antibody drugs is one of the most closely watched emerging targets in the field of inflammatory bowel disease, with no similar drugs currently available on the market globally [1] Industry Summary - The fastest global development progress for TL1A-targeting drugs is being made by Merck, Sanofi, and Roche/Pfizer, all of which have TL1A antibody drugs in Phase III clinical trials [1] - In China, companies such as 3SBio, ZhiXiang JinTai, and HuaShen ZhiYao have also entered Phase I clinical trials for similar TL1A-targeting drugs [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

证券代码：688513 证券简称：苑东生物 公告编号：2026-003 EP-0210 单抗注射液是一款靶向人肿瘤坏死因子样配体 1A（TNF-like ligand 1A，TL1A）的人源化 IgG1 单克隆抗体药物，拟定适应症为炎症性肠病，其作 用机制是通过高效结合人 TL1A，阻止 TL1A 介导的促炎症信号通路，从而发挥 治疗炎症性肠病的作用。 临床前研究表明，EP-0210 单抗注射液药效作用机制明确，在多种炎症性肠 病体内模型中药效显著，具有良好的安全性和有效性；其在靶点活性、体内药效 等方面优于国外同靶点竞品 RVT-3101，有望为炎症性肠病患者带来安全有效的 更多选择。 二、药品 I 期临床试验相关情况 EP-0210 单抗注射液于 2026 年 1 月收到国家药品监督管理局正式批准签发 的《药物临床试验批准通知书》（通知书编号：2026LP00264）。在获得国家药 品监督管理局的药物临床试验批准后，公司启动"EP-0210 单抗注射液在中国健 康成年受试者中的安全性、耐受性和药动学特征的随机、双盲、安慰剂对照、剂 量递增的 I 期临床研究"（临床试验登记号：CTR20260325）。该研 ...

Core Viewpoint - Yuan Dong Biotech (688513.SH) has announced that its wholly-owned subsidiary Chengdu Youluo Biotech Co., Ltd. has initiated a Phase I clinical trial for its self-developed monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first subject having been dosed recently [1] Group 1: Product Development - EP-0210 is a humanized IgG1 monoclonal antibody targeting human tumor necrosis factor-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease [1] - The mechanism of action involves high-affinity binding to TL1A, blocking the pro-inflammatory signaling pathways mediated by TL1A, thereby providing therapeutic effects for inflammatory bowel disease [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, showing good safety and effectiveness [1] - EP-0210 exhibits superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101, potentially offering safer and more effective options for patients with inflammatory bowel disease [1]

Group 1 - The core point of the article is that Yuandong Biotech (688513.SH) announced the completion of the first dosing of its monoclonal antibody drug EP-0210 in a Phase I clinical trial for the treatment of inflammatory bowel disease [2] - The drug EP-0210 is a humanized IgG1 monoclonal antibody targeting the tumor necrosis factor-like ligand 1A (TL1A) [2] - EP-0210 demonstrates superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101 [2]

板块表现： 证券研究报告 医药生物 行业定期报告 hyzqdatemark 2026 年 02 月 09 日 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 分子胶：撬动"不可成药"靶点的创新药新范式 投资评级： 看好（维持） ——医药行业周报（26/2/2-26/2/6） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 证券分析师 联系人 本周医药市场表现分析：2 月 2 日至 2 月 6 日，医药指数上涨 0.14%，相对沪深 300 指数超 额收益为 1.47%。上周市场风格有所变化，白酒等底部消费类资产表现较好，医药行业中的 医疗服务、中药亦有表现。另外，经历短期波动消化后，创新药板块已显现企稳回暖迹象。 我们建议精选基本面强劲、前期调整充分的创新药个股，看好未来股价有望走出新高度，同 时建议积极关注医疗新科技等板块，以及 26 年困境反转的底部个股。1）创新药建议关注，A 股）恒瑞医药、信立泰、泽璟制药、热景生物、科伦药业、上海谊众、康弘药业、华纳药厂、 前沿生物、福元医药、苑东生物、昂利康；港股）中国生物制药、三生制药、信达生物、康 方生物 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The pharmaceutical index in A-shares has shown a slight increase of 0.14% this week and 3.28% year-to-date, outperforming the CSI 300 by 1.41% and 0.85% respectively [3][8] - The report highlights the emergence of molecular glue as a significant trend in the industry, with several successful stocks like RVMD, GLU, and KYMR, and substantial business development (BD) activities [3][15] - The report suggests that molecular glue has the potential to create new blockbuster drugs in oncology and autoimmune diseases, urging investors to focus on domestic companies involved in this area [3][11] Summary by Sections 1. Market Performance - The A-share pharmaceutical index has outperformed the CSI 300 index, with notable gains in traditional Chinese medicine (2.56%), medical services (1.31%), and raw materials (0.64%) [3][8] - The report lists top-performing stocks, including Guangsheng Tang (+29.83%) and HaiXiang Pharmaceutical (+18.64%), while noting declines in stocks like Changshan Pharmaceutical (-15.78%) [8] 2. Molecular Glue - Molecular glue is defined as a class of small molecule drugs that facilitate the binding of E3 ubiquitin ligases to previously unrecognized pathogenic target proteins, leading to their degradation [15] - The report mentions that BMS has two marketed molecular glues with peak sales exceeding $16 billion, and ongoing research into new iterations [3][15] - Domestic companies such as Yuan Dong Biology and Jin Fang Pharmaceutical are noted for their potential in molecular glue development [3][11] 3. R&D Progress and Corporate Developments - The report highlights significant clinical research milestones, including Pfizer's initiation of a Phase II/III trial for its PD-1/VEGF bispecific antibody SSGJ-707 [3] - It also notes that Novartis has submitted its BAFF-R monoclonal antibody for approval in China, and AbbVie has started a Phase II trial for its Bcl-2 inhibitor Venetoclax [3] 4. Recommended Stocks - The report provides a list of recommended stocks across various sectors, including: - CXO and upstream research services: WuXi AppTec, Hao Yuan Pharmaceutical, and Aopumai [11] - Traditional Chinese medicine: Zuo Li Pharmaceutical and Fang Sheng Pharmaceutical [11] - PD-1 PLUS: 3SBio, KANGFANG Biologics, and Innovent Biologics [11] - ADC: Ying En Biologics and Kelong Biotechnology [11] - AI drug development: Jing Tai Holdings [11]

2月6日，苑东生物跌5.02%，截至发稿，报66.20元/股，成交2.12亿元，换手率1.78%，总市值116.86亿 元。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售78.75%，原料药销售9.22%，技术服务及转让6.79%，CMO/CDMO4.01%，其 他1.22%。 从基金十大重仓股角度 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 数据显示，申万菱信基金旗下1只基金重仓苑东生物。申万菱信医药先锋股票A（005433）四季度增持 5.99万股，持有股数18.15万股，占基金净值比例为5.01%，位居第七大重仓股。根据测算，今日浮亏损 失约63.51万元。 责任编辑：小浪快报 申万菱信医药先锋股票A（005433）成立日期2020年11月16日，最新 ...

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

Core Viewpoint - Yuan Dong Biotech (688513) has announced the initiation of Phase I clinical trials for its innovative chemical drug EP-0226, aimed at treating neuropathic pain, in collaboration with the Shanghai Institute of Materia Medica and the Zhongke Zhongshan Drug Innovation Research Institute [1] Group 1 - The first subject has been dosed in the clinical trial for EP-0226 [1] - Preclinical studies indicate that EP-0226 demonstrates superior target selectivity, in vivo analgesic activity, and efficacy compared to the approved drug pregabalin [1] - The safety profile of EP-0226 is reported to be good, suggesting it may provide a safe and effective treatment option for patients suffering from neuropathic pain [1]